----

| CLIN   |   | SUPPLIES/SERVICES               |   | QTY/UNIT |   | EST. COST |    |   | FIXED FEE |   |    | TOTAL EST. CPFF |   |
|--------|--------|---------------------------------|--------|----------|--------|----------------|---------|--------|----------------|--------|---------|---------------------------|--------|
|   |   |                            |   |     |   |           |    |   |           |   |    |                      |   |
| 0001   |   | Product Development Plan        |   | 1 Job    |   |           | [* * *] |   |           |   | [* * *] |                      |   |   | [* * *] |   |
|   |   | (Milestone 1)                   |   |     |   |           |    |   |           |   |    |                      |   |   |   |   |
|   |   |                            |   |     |   |           |    |   |           |   |    |                      |   |   |   |   |
|   |   |                            |   |     |   |           |    |   |           |   |    |                      |   |   |   |   |
| 0002   |   | Clinical Development and        |   | 1 Job    |   |           | [* * *] |   |           |   | [* * *] |                      |   |   | [* * *] |   |
|   |   | Regulatory Plan                 |   |     |   |           |    |   |           |   |    |                      |   |   |   |   |
|   |   | (Milestone 2)                   |   |     |   |           |    |   |           |   |    |                      |   |   |   |   |
|   |   |                            |   |     |   |           |    |   |           |   |    |                      |   |   |   |   |
| 0003   |   | Manufacturing Facility Plan     |   | 1 Job    |   |           | [* * *] |   |           |   | [* * *] |                      |   |   | [* * *] |   |
|   |   | (Milestone 3)                   |   |     |   |           |    |   |           |   |    |                      |   |   |   |   |
|   |   |                            |   |     |   |           |    |   |           |   |    |                      |   |   |   |   |
| 0004   |   | Feasibility Plan                |   | 1 Job    |   |           | [* * *] |   |           |   | [* * *] |                      |   |   | [* * *] |   |
|   |   | (Milestone 4)                   |   |     |   |           |    |   |           |   |    |                      |   |   |   |   |
|   |   |                            |   |     |   |           |    |   |           |   |    |                      |   |   |   |   |
| 0005A  |   | Contractor Defined Milestones - |   | 1 Job    |   |           | [* * *] |   |           |   | [* * *] |                      |   |   | [* * *] |   |
|   |   | Recombinant Seasonal            |   |     |   |           |    |   |           |   |    |                      |   |   |   |   |
|   |   | Influenza Vaccine Milestones    |   |     |   |           |    |   |           |   |    |                      |   |   |   |   |
|   |   | (Milestone 5A)                  |   |     |   |           |    |   |           |   |    |                      |   |   |   |   |

| Contract No. HHSO100201100012C | 2 |
|--------------------------------|---|

----

| 0005B  |   | Contractor Defined Milestones – |   | 1 Job                   |   |    | [* * *] |   |    |   | [* * *] |    |   |   | [* * *] |   |
|--------|--------|---------------------------------------|--------|-------------------------|--------|---------|---------|--------|---------|--------|---------|---------|--------|--------|---------|--------|
|   |   | Recombinant Pandemic                  |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
|   |   | Influenza Vaccine Milestones          |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
|   |   | (Milestone 5B)                        |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
|   |   |                                  |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
| 0006   |   | Draft Security Plan                   |   | [* * *]                 |   | [* * *] |    |   | [* * *] |   |    | [* * *] |   |
|   |   |                                  |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
|   |   |                                  |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
|   |   |                                  |   |                    |   |    |    |   |    |   |    |    |   |
| 0007   |   | Final Security Plan                   |   | [* * *]                 |   | [* * *] |    |   | [* * *] |   |    | [* * *] |   |
|   |   |                                  |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
|   |   |                                  |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
|   |   |                                  |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
| 0008   |   | Technical Progress Reports            |   | 36 reports of |   |    | [* * *] |   |    |   | [* * *] |    |   |   | [* * *] |   |
|   |   | (Including EVM) and Executive         |   | each                    |   |    |    |   |    |   |    |    |   |   |    |   |
|   |   | Summary                               |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
|   |   |                                  |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
| 0009   |   | Draft Final Report                    |   | [* * *]                 |   | [* * *] |    |   | [* * *] |   |    | [* * *] |   |
|   |   |                                  |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
|   |   |                                  |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
|   |   |                                  |   |                    |   |    |    |   |    |   |    |    |   |   |    |   |
| 0010   |   | Final Report                          |   | 1 Report                |   |    | [* * *] |   |    |   | [* * *] |    |   |   | [* * *] |   |

| Optional |   |                       |   |                    |   |           |    |   |           |   |    |                      |   |
|----------|--------|----------------------------|--------|-------------------------|--------|----------------|---------|--------|----------------|--------|---------|---------------------------|--------|
| CLIN     |   | SUPPLIES/SERVICES          |   | QTY/UNIT                |   | EST. COST |    |   | FIXED FEE |   |    | TOTAL EST. CPFF |   |
| 0011A    |   | Additional Contractor      |   | 1 Job                   |   |           | [* * *] |   |           |   | [* * *] |                      |   |   | [* * *] |   |
|     |   | Defined Milestones -       |   |                    |   |           |    |   |           |   |    |                      |   |   |   |   |
|     |   | Recombinant Seasonal       |   |                    |   |           |    |   |           |   |    |                      |   |   |   |   |
|     |   | Influenza Vaccine          |   |                    |   |           |    |   |           |   |    |                      |   |   |   |   |
|     |   |                       |   |                    |   |           |    |   |           |   |    |                      |   |   |   |   |
| 0011B    |   | Additional Contractor      |   | 1 Job                   |   |           | [* * *] |   |           |   | [* * *] |                      |   |   | [* * *] |   |
|     |   | Defined Milestones – |   |                    |   |           |    |   |           |   |    |                      |   |   |   |   |
|     |   | Recombinant Pandemic       |   |                    |   |           |    |   |           |   |    |                      |   |   |   |   |
|     |   | Influenza Vaccine          |   |                    |   |           |    |   |           |   |    |                      |   |   |   |   |
|     |   |                       |   |                    |   |           |    |   |           |   |    |                      |   |   |   |   |
| 0012     |   | Technical Progress Reports |   | 24 reports of |   |           | [* * *] |   |           |   | [* * *] |                      |   |   | [* * *] |   |
|     |   | (Including EVM) and        |   | each                    |   |           |    |   |           |   |    |                      |   |   |   |   |
|     |   | Executive Summary          |   |                    |   |           |    |   |           |   |    |                      |   |   |   |   |
|     |   |                       |   |                    |   |           |    |   |           |   |    |                      |   |   |   |   |
| 0013     |   | Draft Final Report         |   | [* * *]                 |   | [* * *]        |    |   | [* * *]        |   |    | [* * *]                   |   |
|     |   |                       |   |                    |   |           |    |   |           |   |    |                      |   |   |   |   |
|     |   |                       |   |                    |   |           |    |   |           |   |    |                      |   |   |   |   |
|     |   |                       |   |                    |   |           |    |   |           |   |    |                      |   |   |   |   |
| 0014     |   | Final Report               |   | 1 Report                |   |           | [* * *] |   |           |   | [* * *] |                      |   |   | [* * *] |   |

| Contract No. HHSO100201100012C | 3 |
|--------------------------------|---|

----

| Optional |   | SUPPLIES/   |   |             |   |            |    |   |           |   |    |           |   |   |                      |   |
|----------|--------|-----------------------|--------|------------------|--------|-----------------|---------|--------|----------------|--------|---------|----------------|--------|--------|---------------------------|--------|
| CLIN     |   | SERVICES              |   | QTY/UNIT         |   | UNIT PRICE |    |   | EST. COST |   |    | FIXED FEE |   |   | TOTAL EST. CPFF |   |
| 0015     |   | The Contractor shall  |   | 150,000/15 mcg   |   |            | [* * *] |   |           |   | [* * *] |           |   |   | [* * *]                   |   |   |   | [* * *] |   |
|     |   | manufacture bulk      |   | dose equivalents |   |            |    |   |           |   |    |           |   |   |                      |   |   |   |   |   |
|     |   | Recombinant           |   | (Bulk)**         |   |            |    |   |           |   |    |           |   |   |                      |   |   |   |   |   |
|     |   | Influenza Vaccine     |   |             |   |            |    |   |           |   |    |           |   |   |                      |   |   |   |   |   |
|     |   | candidate*            |   |             |   |            |    |   |           |   |    |           |   |   |                      |   |   |   |   |   |

|   | a) | Acquisition, by purchase or lease, of any interest in real property; |
|--------|----|----------------------------------------------------------------------|

|   | b) | Special rearrangement or alteration of facilities; |
|--------|----|----------------------------------------------------|

|   | c) | Purchase of lease of any item of general purpose office furniture or office equipment regardless of dollar value; (General purpose equipment is defined as any items of personal property which are usable for purposes other than research, such as office equipment and furnishings, pocket calculators, etc.); |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | d) | Travel Costs; |
|--------|----|---------------|

|   | e) | Consultant Costs; |
|--------|----|-------------------|

|   | f) | Subcontracts; |
|--------|----|---------------|

|   | g) | Patient Care Costs; and |
|--------|----|-------------------------|

|   | h) | Accountable Government Property (defined as both real and personal property with an acquisition cost of $1,000 or more and a life expectancy of more than two years) and “sensitive items” (defined and listed in the Contractor’s Guide of Government Property), regardless of acquisition value. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| A. | PURPOSE |
|----|---------|

| Contract No. HHSO100201100012C | 4 |
|--------------------------------|---|

----

| I. | Milestone 1: Within three (3) months of contract award, the Contractor shall provide to HHS for review and acceptance a comprehensive milestone-driven Product Development Plan for recombinant seasonal and pandemic influenza vaccines. The Plan shall be inclusive of pre-clinical and clinical activities performed and completed prior to a contract award and those clinical and manufacturing activities to be performed post-contract award. The Plan shall be a high-level overview and include the following elements: |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | A. | Gantt chart timeline or equivalent. |
|--------|----|-------------------------------------|

|   | B. | Description of the process development and scale-up of recombinant vaccine manufacturing. |
|--------|----|-------------------------------------------------------------------------------------------|

|   | C. | Description of clinical and consistency lot manufacturing to support process validation, clinical evaluation and FDA Center for Biologics Evaluation and Research (CBER) product licensure. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | D. | Description of the general clinical development plan including development and validation of clinical sample assays. |
|--------|----|----------------------------------------------------------------------------------------------------------------------|

|   | E. | Description of product lot release assay development including assay specifications and validation. |
|--------|----|-----------------------------------------------------------------------------------------------------|

|   | F. | Regulatory master plan that focuses on the critical pathway to product licensure. |
|--------|----|-----------------------------------------------------------------------------------|

|   | G. | Cost-accounting system based on the original budget estimates (that includes earned value management) to monitor all costs related to the contract award for both prime and sub-Contractors on a real time basis. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Contract No. HHSO100201100012C | 5 |
|--------------------------------|---|

----

| II. | Milestone 2: Within three (3) months of contract award, the Contractor shall submit to HHS for review and acceptance, a comprehensive, integrated Clinical Development and Regulatory Plan. The following issues shall be addressed in the Plan: |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | A. | A summary of pre-clinical studies including consultation(s) with the FDA Center for Biologics Evaluation and Research (CBER) incorporated as an appendix to the milestone report. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | B. | A detailed description of clinical evaluation shall be integrated with the manufacturing plans using the most current and available information including consultation with CBER. Clinical trials performed as a result of this solicitation shall include any Phase 1, Phase 2, and Phase 3 trials needed to achieve U.S. licensure. Trials shall include children, adults, and the elderly, as needed, to support licensure for both low and high-risk populations. Given the duration, cost, and importance of clinical trials, the plan for each clinical trial shall clearly indicate key outcomes, populations, study sites and collaborators, analytic strategy, sample size, timelines, and other key components. Studies related to pandemic-like vaccine shall be done using recombinant influenza vaccine to a relevant influenza virus strain to be designated by HHS (i.e., H5N1, H1N1, etc.) A summary of available clinical lot manufacturing results, provisional lot release specifications, completed Phase 1 trials and any additional stages of product development that have been completed shall be incorporated as an appendix to the milestone report. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | C. | A detailed description of regulatory activities shall be integrated with all products, clinical testing and manufacturing activities using the most current and available information, including consultation with CBER. A riskassessment and mitigation plan addressing potential manufacturing, clinical and regulatory obstacles that might prevent or delay licensure as well as a plan for the production and distribution of vaccine in the case of emergency use authorization shall be included. Issues suitable for risk assessment include recombinant DNA constructs, cell lines, assay development, process yields and facility management. Mitigation plans shall include decision trees where applicable. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| III. | Milestone 3: Within nine (9) months of contract award, the Contractor shall provide HHS for review and acceptance a Manufacturing Facility Plan describing the design, construction, commissioning, qualification and validation of a U.S.-based facility to produce the Contractor’s recombinant seasonal and pandemic-like influenza vaccines. The Plan shall contain appropriate information concerning the following elements: |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | A. | Site selection criteria, including site user requirement specifications, descriptions of site utilities and infrastructure, descriptions of local, state and federal permitting issues and security planning considerations. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | B. | A facility regulatory compliance plan that addresses cGMP standards, NIH, CDC, USDA and WHO biosafety standards, USDA animal testing standards, National Fire Protection Agency standards, DHS security issues and OSHA compliance. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | C. | Manufacturing processes that includes descriptions of upstream and downstream processing, formulation, filling  and finishing unit operations, bulk and finished product acceptance specifications, overall capacity needed to meet contract requirements, manufacturing support operations such as solution preparation, storage and distribution, glassware washing and sterilization, clean-in-place and steam-in-place operations, a risk management plan at each stage of production, process flow diagrams, equipment capacity calculations, an automation plan and an equipment list detailing sizing capacity criteria, utility requirements, dimensions, clearances weights, mounting and purchasing lead times. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | D. | Architectural/structural plans that includes concept functional designs, descriptions, and diagrams of space requirements, adjacency plans, floor plans, equipment layouts, material, product and personnel flows, solid, liquid contaminated and other waste flows, and an air balance description or diagram detailing zoning, pressurization, air flows and air quality classification. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | E. | Process and building/mechanical engineering including energy balances, utility flow diagrams, automation plan, equipment lists and a preliminary layout. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | F. | A proposed construction schedule including installation, commissioning and installation/operational/performance qualification and a risk mitigation analysis. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Contract No. HHSO100201100012C | 6 |
|--------------------------------|---|

----

|   | G. | A description of the manufacturing facility quality assurance and regulatory acceptance including quality systems, the validation master plan and regulatory milestones. |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| IV. | Milestone 4: Within twelve (12) months of contract award, the Contractor shall provide HHS for review and acceptance a Feasibility Plan to manufacture, test, and release final container product containing recombinant pandemic-like influenza vaccine within 12 weeks of a pandemic declaration with a surge capacity of 50 million doses within six (6) months. The Plan shall include the following elements: |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | A. | A process description, including a summary of process data that describes the yield and purification efficiencies of key process steps. |
|--------|----|-----------------------------------------------------------------------------------------------------------------------------------------|

|   | B. | A comparison of process data that describes the significance of process scale-up and strain variability on production capacity. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------|

|   | C. | Proposed production schedules including detailed timelines for each production step from accessibility of pandemic influenza viral nucleotide sequences or receipt of pandemic influenza virus reference strain to release of initial lot(s) of 50 million doses of final container vaccine product during a pandemic. Additionally, a description of material management and the number of doses of vaccine released each week after pandemic declaration shall be provided. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | D. | A bulk and fill-finish manufacturing capacity analysis for pandemic influenza vaccines. |
|--------|----|-----------------------------------------------------------------------------------------|

|   | E. | A description of process optimization activities. |
|--------|----|---------------------------------------------------|

|   | F. | Dose calculations and contingency plans to address the need for higher dosages of the active product ingredient. |
|--------|----|------------------------------------------------------------------------------------------------------------------|

|   | G. | A pre-pandemic facility management plan including a pandemic preparedness plan. |
|--------|----|---------------------------------------------------------------------------------|

|   | H. | A pandemic facility management plan including change procedures for pandemic operations and operation under Emergency Use Authorization (EUA). |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------|

| V. | Milestone 5a and 5b: Contractor Defined Milestones. The Contractor shall provide a work breakdown structure including comprehensive and integrated timelines (Gantt chart or equivalent) and major milestones to complete the remaining scope of work as relevant given the stage of vaccine development and evaluation toward product licensure. The Contractor shall propose milestones, at which time data will be presented, summarizing results of prior activities and new plans and protocols that will be submitted for review and approval in order to guide all subsequent activities. Milestones for recombinant seasonal (5a) and pandemic-like (5b) influenza vaccines shall be provided to track program progress and cost reimbursements. Potential milestones may include manufacturing of an investigational lot of vaccine, validation of facilities, systems and equipment, validation of Quality Control product lot release methods, validation of manufacturing processes, stability study programs, consistency lot manufacturing, completion of a clinical trial and progress to a new phase of vaccine evaluation, submission of a license application, GMP Consistency Lots Manufacturing, Phase 3 Lots Testing and Release, Reproductive Toxicology study(ies), Phase 2 Clinical trials in healthy adults, etc. Following the Project Officer/Contracting Officer’s Technical Representative (COTR) acceptance of the Contractor Defined Milestones, the Contracting Officer may modify this contract to incorporate the Contractor Defined Milestones, work breakdown structure and Gantt chart. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| VI. | Manufacturing Standards:  The USG reserves the right to inspect the Contractor’s facilities for cGMP compliance.   HHS will audit manufacturing, testing and other relevant sites.   Focus areas will include manufacturing, quality systems and regulatory affairs relative to the contract milestone activities within six (6) months of contract award.   Any deficiencies observed in the audit will require remediation.   Within three (3) months after receiving the audit report, a time-plan for remediation must be in place and remediation shall be complete within the Base Period of the contract. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Contract No. HHSO100201100012C | 7 |
|--------------------------------|---|

----

| C.2.1 | Managerial Approach |
|-------|---------------------|

| Contract No. HHSO100201100012C | 8 |
|--------------------------------|---|

----

|   | 1. | Plan all work scope for the program to completion. |
|--------|----|----------------------------------------------------|

|   | 2. | Break down the program work scope into finite pieces that can be assigned to a responsible person or organization for control of technical, schedule, and cost objectives. |
|--------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 3. | Integrate program work scope, schedule, and cost objectives into a performance measurement baseline plan against which accomplishments may be measured. Control changes to the baseline. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 4. | Use actual cost incurred and recorded in accomplishing the work performed. |
|--------|----|----------------------------------------------------------------------------|

|   | 5. | Objectively assess accomplishments at the work performance level. |
|--------|----|-------------------------------------------------------------------|

|   | 6. | Analyze significant variances from the plan, forecast impacts, and prepare an estimate at completion based on performance to date and work to be performed. |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | 7. | Use Performance Based information in the company's management processes. |
|--------|----|--------------------------------------------------------------------------|

| C.2.2 | Performance Measurement Baseline (PMB) |
|-------|----------------------------------------|

| C.2.3 | Integrated Baseline Review (IBR) |
|-------|----------------------------------|

|   | · | Demonstrate that there is a logical sequence of effort consistent with the contract schedule; |
|--------|--------|-----------------------------------------------------------------------------------------------|

|   | · | Demonstrate the validity of the allocated cost accounts and budgets, both in terms of total resources and scheduling; |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------|

|   | · | Support BARDA’s technical assessment of the performance measurement methodologies and variance analysis reporting thresholds that the Contractor is using to measure progress; |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Support BARDA’s technical assessment of quality metrics; |
|--------|--------|----------------------------------------------------------------|

|   | · | Verify that the cost, schedule, and technical plans are integrated. (The technical content of control accounts and work packages is consistent with the contract scope of work, the WBS and the WBS dictionary). |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| C.2.4 | Contract Performance Report (CPR) |
|-------|-----------------------------------|

| C.2.5 | Integrated Master Schedule |
|-------|----------------------------|

| C.2.6 | Work Breakdown Structure |
|-------|--------------------------|

| Contract No. HHSO100201100012C | 9 |
|--------------------------------|---|

----

| C.2.7 | Risk Management Plan |
|-------|----------------------|

| I. | Technical Progress Reports: On the fifteenth of each month for the previous calendar month, the Contractor shall submit a report to the Project Officer/COTR and the Contracting Officer. The format and type of Technical Progress Report and Executive Summary will be provided by the Project Officer/COTR. Technical Progress Reports will include project timelines, milestones and summaries of product manufacturing, testing and clinical evaluation. A Technical Progress Report will not be required for the periods when a Final Report is due. The Contractor shall submit one copy of the Technical Progress Report electronically via e-mail. Any attachments to the e-mail report shall be submitted in Microsoft Word, Excel, PowerPoint, Microsoft Project and/or Adobe Acrobat PDF files. Such reports shall include the following specific information: |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | A. | Title page containing Technical Progress Report, the contract number and title, the period of performance or milestone being reported, the Contractor's name, address, and other contact information, the author(s), and the date of submission; |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | B. | Introduction/Background - An introduction covering the purpose and scope of the contract effort; |
|--------|----|--------------------------------------------------------------------------------------------------|

|   | C. | Progress - The report shall detail, document, and summarize the results of work performed, test results, and milestones achieved during the period covered. Also to be included is a summary of work planned for the next reporting period including overall progress towards obtaining FDA approvals and licensure on new influenza vaccine(s); |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | D. | Issues - Issues resolved, new issues and outstanding issues are enumerated with options and recommendations for resolution. An explanation of any difference between planned progress and actual progress, why the differences have occurred, and, if project activity is delinquent, then what corrective steps are planned. Revised timelines are provided. |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | E. | Invoices – Summary of any invoices submitted during the reporting period. |
|--------|----|---------------------------------------------------------------------------------|

|   | F. | Action Items – Summary table of activities or tasks to be accomplished by a certain date and by whom. |
|--------|----|-------------------------------------------------------------------------------------------------------------|

|   | G. | Distribution List – A list of persons receiving the Technical Progress report |
|--------|----|-------------------------------------------------------------------------------------|

|   | H. | Attachments – Results on the project are provided as attachments |
|--------|----|------------------------------------------------------------------------|

| III. | The Executive Summary, which shall accompany each Technical Progress Report, will be formatted in Microsoft Power Point presentations and include the following: |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | A. | Title page containing Executive Title, the contract number and title, the period of performance or milestone being reported, the Contractor's name and the date of submission; |
|--------|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | B. | Project Progress presented as milestone events, test results, tasks and other activities achieved during the reporting period as talking point bullets; |
|--------|----|---------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | C. | Project Issues presented headings and each item as a talking point bullet. |
|--------|----|----------------------------------------------------------------------------|

| IV. | Final Reports – The Contractor shall submit a Draft Final Report for the Base Period and Option Period One to the Project Officer/COTR and Contracting Officer within 45 calendar days prior to the contract expiration date. The Project Officer/COTR will review the draft report and provide the Contracting Officer with comments within 15 calendar days after receipt. The Final Report shall be corrected by the Contractor, if necessary and the final version delivered by the expiration date of the contract. The Contractor shall submit a comprehensive Final Report for the Base Period and Option Period One that shall detail, document and summarize the results of the entire contract work. The report shall explain comprehensively the results achieved. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Contract No. HHSO100201100012C | 10 |
|--------------------------------|----|

----

| Project Officer/COTR        | Contracting Officer         |
|-----------------------------|-----------------------------|
| HHS/OS/ASPR/BARDA           | HHS/OS/ASPR/AMCG            |
| 330 Independence Avenue, SW | 330 Independence Avenue, SW |
| Room G640                   | Room G640                   |
| Washington, D.C. 20201      | Washington, D.C. 20201      |

| PERIOD            |   | PERFORMANCE PERIOD                                                                                                                  |
|-------------------|--------|-------------------------------------------------------------------------------------------------------------------------------------|
|              |   |                                                                                                                                |
| Option Period One |   | Thirty Six (36) months after the effective date of the contract through sixty (60) months after the effective date of the contract. |

| Contract No. HHSO100201100012C | 11 |
|--------------------------------|----|

----

| A. | The following contract deliverables and technical reports are required for the Base Period of this contract. |
|----|--------------------------------------------------------------------------------------------------------------|

| CLIN   |         | Deliverable                              |         | Quantity                       |         | Due Date                      |
|--------|--------------|------------------------------------------|--------------|--------------------------------|--------------|-------------------------------|
|   |         |                                     |         |                           |         |                          |
| 0001   |         | Product Development Plan                 |         | Original – C.O.          |         | WithinThree(3)months          |
|   |         | (Milestone 1)                            |         | 2Copies – P.O.           |         | after contract award.         |
|   |         |                                     |         | 1Electronic Copy – P.O.  |         |                          |
|   |         |                                     |         |                           |         |                          |
| 0002   |         | Clinical Development and Regulatory Plan |         | Original – C.O.          |         | WithinThree(3)months          |
|   |         | (Milestone 2)                            |         | 2Copies – P.O.           |         | after contract award.         |
|   |         |                                     |         | 1Electronic Copy – P.O.  |         |                          |
|   |         |                                     |         |                           |         |                          |
| 0003   |         | Manufacturing Facility Plan              |         | Original – C.O.          |         | Within Nine (9) months after  |
|   |         | (Milestone 3)                            |         | 2Copies – P.O.           |         | contract award.               |
|   |         |                                     |         | 1Electronic Copy – P.O.  |         |                          |
|   |         |                                     |         |                           |         |                          |
| 0004   |         | Feasibility Plan                         |         | Original – C.O.          |         | Within Twelve (12) months     |
|   |         | (Milestone 4)                            |         | 2Copies – P.O.           |         | after contract award.         |
|   |         |                                     |         | 1Electronic Copy – P.O.  |         |                          |
|   |         |                                     |         |                           |         |                          |
| 0005A  |         | Contractor Defined Milestones            |         | Original – C.O.          |         | Within thirty-six (36) months |
|   |         | (Milestone 5A)                           |         | 2Copies – P.O.           |         | after contract award.         |
|   |         |                                     |         | 1Electronic Copy – P.O.  |         |                          |
|   |         |                                     |         |                           |         |                          |
| 0005B  |         | Contractor Defined Milestones            |         | Original – C.O.          |         | Within thirty-six (36) months |
|   |         | (Milestone 5B)                           |         | 2Copies – P.O.           |         | after contract award.         |
|   |         |                                     |         | 1Electronic Copy – P.O.  |         |                          |
|   |         |                                     |         |                           |         |                          |
| 0006   |         | Draft Security Plan                      |         | Original – C.O.          |         | Within thirty (30) days after |
|   |         |                                     |         | 2Copies – P.O.           |         | contract award.               |
|   |         |                                     |         | 1Electronic Copy – P.O.  |         |                          |
|   |         |                                     |         |                           |         |                          |
| 0007   |         | Final Security Plan                      |         | Original – C.O.          |         | Within thirty (30) days after |
|   |         |                                     |         | 2Copies – P.O.           |         | USG’s final comments.   |
|   |         |                                     |         | 1Electronic Copy – P.O.  |         |                          |
|   |         |                                     |         |                           |         |                          |
| 0008   |         | Technical Progress Reports (Including    |         | Original – C.O.          |         | Due on/before the 15th of the |
|   |         | EVM) and Executive Summary               |         | 2Copies – P.O.           |         | monthfortheprevious           |
|   |         |                                     |         | 1Electronic Copy – P.O.  |         | calendarmonth.See             |
|   |         |                                     |         |                           |         | ARTICLEC.2.Notdue             |
|   |         |                                     |         |                           |         | when Final Report is due.     |
|   |         |                                     |         |                           |         |                          |
| N/A    |         | Contract Financial Report                |         | Original – C.O.          |         | Due on a quarterly basis      |
|   |         |                                     |         | 2Copies – P.O.           |         | on/before the 15th of the     |
|   |         |                                     |         | 1Electronic Copy – P.O.  |         | month. Not due when Final     |
|   |         |                                     |         |                           |         | Report is due. See            |
|   |         |                                     |         |                           |         | ARTICLE G.5.                  |
|   |         |                                     |         |                           |         |                          |
| 0009   |         | Draft Final Report                       |         | Original – C.O.          |         | Due 45 days prior to the      |
|   |         |                                     |         | 2Copies – P.O.           |         | expirationdateofthe           |
|   |         |                                     |         | 1Electronic Copy – P.O.  |         | contract.                     |
|   |         |                                     |         |                           |         |                          |
| 0010   |         | Final Report                             |         | Original – C.O.          |         | Due on/before the expiration  |
|   |    |                                     |    | 2Copies – P.O.           |    | date of the contract.         |
|   |         |                                     |         | 1 Electronic Copy – P.O. |         |                          |

| Contract No. HHSO100201100012C | 12 |
|--------------------------------|----|

----

| B. | The following contract deliverables and technical reports are required for  Option Period One of this contract. |
|----|---------------------------------------------------------------------------------------------------------------------------|

| CLIN   |   | Deliverable                               |   | Quantity                      |   | Due Date                 |
|--------|--------|-------------------------------------------|--------|-------------------------------|--------|-------------------------------|
| 0011A  |   | Remaining Contractor Defined Milestones - |   | Original – C.O.         |   | Within twenty-four (24)       |
|   |   | Recombinant Seasonal Influenza Vaccine    |   | 2Copies – P.O.          |   | monthsafteroptionperiod       |
|   |   |                                      |   | 1Electronic Copy – P.O. |   | one award.                    |
|   |   |                                      |   |                          |   |                          |
| 0011B  |   | Remaining Contractor Defined Milestones - |   | Original – C.O.         |   | Within twenty-four (24)       |
|   |   | Recombinant Pandemic Influenza Vaccine    |   | 2Copies – P.O.          |   | monthsafteroptionperiod       |
|   |   |                                      |   | 1Electronic Copy – P.O. |   | one award.                    |
|   |   |                                      |   |                          |   |                          |
| 00012  |   | Technical Progress Reports (Including     |   | Original – C.O.         |   | Due on/before the 15th of the |
|   |   | EVM) and Executive Summary                |   | 2Copies – P.O.          |   | monthfortheprevious           |
|   |   |                                      |   | 1Electronic Copy – P.O. |   | calendarmonth.See             |
|   |   |                                      |   |                          |   | ARTICLE C.2.Not due           |
|   |   |                                      |   |                          |   | when Final Report is due.     |
|   |   |                                      |   |                          |   |                          |
| N/A    |   | Contract Financial Report                 |   | Original – C.O.         |   | Due on a quarterly basis      |
|   |   |                                      |   | 2Copies – P.O.          |   | on/before the 15th of the     |
|   |   |                                      |   | 1Electronic Copy – P.O. |   | month.Not due when Final      |
|   |   |                                      |   |                          |   | Reportisdue.See               |
|   |   |                                      |   |                          |   | ARTICLE G.5.                  |
|   |   |                                      |   |                          |   |                          |
| 0013   |   | Draft Final Report                        |   | Original – C.O.         |   | Due 45 days prior to the      |
|   |   |                                      |   | 2Copies – P.O.          |   | expirationdateofthe           |
|   |   |                                      |   | 1Electronic Copy – P.O. |   | contract.                     |
|   |   |                                      |   |                          |   |                          |
| 0014   |   | Final Report                              |   | Original – C.O.         |   | Due on/before the expiration  |
|   |   |                                      |   | 2Copies – P.O.          |   | date of the contract.         |
|   |   |                                      |   | 1Electronic Copy – P.O. |   |                          |

| C. | The following contract deliverables are required for Optional CLIN 0015 of this contract. |
|----|-------------------------------------------------------------------------------------------|

| 1. | The funded quantity, based on the exercise of optional CLIN 0015, shall be delivered to a location(s) to be designated by USG. The funded quantity by the exercise of the optional CLIN 0015 must be delivered to a location(s) to be designated by USG within a timeframe not to exceed six (6) months after the optional CLIN is exercised. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | A FDA approval/licensure letter for the recombinant seasonal and pandemic influenza vaccine or copies of the Emergency Use Authorizations (EUA). |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------|

| 3. | Copies of all FDA inspection reports, including Form 483, for all aspects of final finished product manufacturing and any cGMP inspection reports and copies of correspondence with FDA. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Contract No. HHSO100201100012C | 13 |
|--------------------------------|----|

----

| NAME    |         | TITLE                               |
|---------|--------------|-------------------------------------|
| [* * *] |         | Principal Investigator              |
| [* * *] |         | Program Manager                     |
| [* * *] |         | Process & Manufacturing         |
| [* * *] |         | Analytical & Quality Operations |
| [* * *] |         | Vice President Clinical Development |
| [* * *] |         | Regulatory Affairs                  |
| [* * *] |    | Quality Assurance                   |

| Contract No. HHSO100201100012C | 14 |
|--------------------------------|----|

----

|   | HHS/OS/ASPR/AMCG                                    |
|--------|-----------------------------------------------------|
|   | 330 Independence Avenue, SW, Room G640              |
|   | Washington, DC 20201                                |
|   | Attn:  RoseMary Mann, Contracting Officer |
|   | Contract No. HHSO100201100012C                      |

| a. | Financial reports on the attached form, Financial Report of Individual Project/Contract (Attachment 2), shall be submitted by the Contractor in accordance with the instructions, which accompany the form, no later than the 15th working day after the close of the reporting period. The line entries for subdivisions of work and elements of cost (expenditure categories) which shall be reported within the total contract are discussed in paragraph e., below. Subsequent changes and/or additions in the line entries shall be made in writing. Financial reports shall be submitted by the Contractor to the address specified in Block 7 on the face page of the contract. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b. | Unless otherwise stated in that part of the instructions entitled, “Preparation Instructions”, all columns A through J shall be  completed for each report submitted. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| c. | The first financial report shall cover the period consisting of the FIRST FULL THREE CALENDAR MONTHS following the date of the contract, in addition to any fractional part of the initial month. Thereafter, reports will be on a quarterly basis. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| d. | The Contracting Officer may require the Contractor to submit detailed support for costs contained in one or more interim financial reports. This clause does not supersede the record retention requirements in FAR Part 4.7. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| e. | The listing of expenditure categories to be reported is incorporated within Attachment 2 entitled, “Financial Report of  Individual Project/Contract”, located in SECTION J and made a part of this contract. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| f. | The financial report must be in compliance with EVMS requirements and the format shall be approved by the Government and include all negotiated budget elements. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| g. | The Government may unilaterally revise the expenditure categories to reflect the allotment of additional funds. |
|----|-----------------------------------------------------------------------------------------------------------------|

|   | · | Fringe Benefits – [* * *] |
|--------|--------|---------------------------------|

|   | · | Overhead – [* * *] |
|--------|--------|--------------------------|

|   | · | General and Administrative (G&A) on total costs – [* * *] |
|--------|--------|---------------------------------------------------------------------|

|   | · | General and Administrative (G&A) on subcontractors – [* * *] |
|--------|--------|------------------------------------------------------------------------|

| Contract No. HHSO100201100012C | 15 |
|--------------------------------|----|

----

| a. | In addition to the requirements of the clause, GOVERNMENT PROPERTY, incorporated in SECTION I of this contract, the Contractor shall comply with the provisions of HHS Publication, “Contractor’s Guide for Control of Government Property”, which is incorporated into this contract by reference.  This document can be accessed at: |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b. | Notwithstanding the provisions outlined in the HHS Publication, “Contractor’s Guide for Control of Government Property”, which is incorporated in this contract in paragraph a. above, the Contractor shall use the form entitled, “Report of Government Owned, Contractor Held Property” (Attachment 3) for submitting summary reports or for performing annual inventories required under this contract, as directed by the Contracting Officer or his/her designee.  This form is included as an attachment in SECTION J of this contract. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a.) | No contract involving human subjects research shall be awarded until acceptable assurance has been given that the project or activity will be subject to initial and continuing review by an appropriate institutional review committee(s) as described in 45 CFR Part 46. Contracts involving human subjects will not be awarded to an individual unless the individual is affiliated with or sponsored by an institution that has an Office for Human Research Protections (OHRP) approved assurance of compliance in place and will assume responsibility for safeguarding the human subjects involved. The OHRP web site is: http://www.hhs.gov/ohrp. The Contractor further agrees to provide certification at least annually that the institutional review board has reviewed and approved the procedures which involve human subjects in accordance with 45 CFR  Part 46 and the Assurance of Compliance. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b) | The Contractor shall bear full responsibility for the performance of all work and services involving the use of human subjects under this contract in a proper manner and as safely as is feasible. The parties hereto agree that the Contractor retains the right to control and direct the performance of all work under this contract. Nothing in this contract shall be deemed to constitute the Contractor or any subcontractor, agent or employee of the Contractor, or any other person, organization, institution or group of any kind whatsoever, as the agent or employee of the Government. The Contractor agrees that it has entered into this contract and will discharge its obligations, duties and undertakings and the work pursuant thereto, whether requiring professional judgment or otherwise, as an independent Contractor without imputing liability on the part of the Government for the acts of the Contractor or its employees. |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Contract No. HHSO100201100012C | 16 |
|--------------------------------|----|

----

| c) | If at any time during performance of this contract, the Contracting Officer determines, in consultation with the OHRP, that the Contractor is not in compliance with any of the requirements and/or standards stated in paragraphs (a) and (b) above, the Contracting Officer may immediately suspend, in whole or in part, work and further payments under this contract until the Contractor corrects such noncompliance. Notice of the suspension may be communicated by telephone and confirmed in writing. |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| d) | If the Contractor fails to complete corrective action within the period of time designated in the Contracting Officer’s written notice of suspension, the Contracting Officer may, in consultation with OHRP, terminate this contract in whole or in part, and the Contractor’s name may be removed from the list of those Contractors with approved Health and Human Services Human Subject Assurances. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Contract No. HHSO100201100012C | 17 |
|--------------------------------|----|

----

| Contract No. HHSO100201100012C | 18 |
|--------------------------------|----|

----

| a. | Maintain a written, enforceable policy on conflict of interest that complies with 45 CFR Part 94 and inform each investigator of the policy, the investigator's reporting responsibilities and the applicable regulations. The Contractor must take reasonable steps to ensure that investigators working as collaborators or subcontractors comply with the regulations. |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b. | Designate an official(s) to solicit and review financial disclosure statements from each investigator participating in HHS-funded research. Based on established guidelines consistent with the regulations, the designated official(s) must determine whether a conflict of interest exists, and if so, determine what actions shall be taken to manage, reduce or eliminate such conflict. A conflict of interest exists when the designated official(s) reasonably determines that a Significant Financial Interest could directly and significantly affect the design, conduct or reporting of the HHS-funded research. The Contractor may require the management of other conflicting financial interests in addition to those described in this paragraph, as it deems appropriate. Examples of conditions or restrictions that might be imposed to manage actual or potential conflicts of interests are included in 45 CFR Part 94, under Management of Conflicting Interests. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| c. | Require all financial disclosures to be updated during the period of the award, either on an annual basis or as new reportable Significant Financial Interests are obtained. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| d. | Maintain records, identifiable to each award, of all financial disclosures and all actions taken by the Contractor with respect to each conflicting interest 3 years after final payment or, where applicable, for the other time periods specified in 48 CFR Part 4, subpart 4.7, Contract Records Retention. |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| e. | Establish adequate enforcement mechanisms and provide for sanctions where appropriate. |
|----|----------------------------------------------------------------------------------------|

| Contract No. HHSO100201100012C | 19 |
|--------------------------------|----|

----

|   | Office of Inspector General             |
|--------|-----------------------------------------|
|   | Department of Health and Human Services |
|   | ATTN: HOTLINE                           |
|   | P.O. Box 23489                          |
|   | Washington, D.C. 20026                  |

| Contract No. HHSO100201100012C | 20 |
|--------------------------------|----|

----

| A. | Pursuant to the current HHS annual appropriations act, Contractors funded with Federal dollars, in whole or in part, acknowledges Federal funding when issuing statements, press releases, request for proposals, bid solicitations and other documents. Contractors are required to state (1) the percentage and dollar amounts of the total program or project costs financed with Federal money, and (2) the percentage and dollar amount of the total costs financed by nongovernmental sources. |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| B. | Publication and Publicity |
|----|---------------------------|

| C. | Press Releases |
|----|----------------|

| Contract No. HHSO100201100012C | 21 |
|--------------------------------|----|

----

| Contract No. HHSO100201100012C | 22 |
|--------------------------------|----|

----

| a. | FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES: |
|----|------------------------------------------------------------------|

| FAR             |         |     |         |                                                                                                                                                     |
|-----------------|--------------|----------|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|
| CLAUSE NO. |         | DATE     |         | TITLE                                                                                                                                                    |
| 52.202-1        |         | Jul 2004 |         | Definitions (Over $100,000)                                                                                                                              |
| 52.203-3        |         | Apr 1984 |         | Gratuities (Over $100,000)                                                                                                                               |
| 52.203-5        |         | Apr 1984 |         | Covenant Against Contingent Fees (Over $100,000)                                                                                                         |
| 52.203-6        |         | Sep 2006 |         | Restrictions on Subcontractor Sales to the Government (Over $100,000)                                                                                    |
| 52.203-7        |         | Oct 2010 |         | Anti-Kickback Procedures (Over $150,000)                                                                                                                 |
| 52.203-8        |         | Jan 1997 |         | Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity (Over $100,000)                                                         |
| 52.203-10       |         | Jan 1997 |         | Price or Fee Adjustment for Illegal or Improper Activity (Over $100,000)                                                                                 |
| 52.203-12       |         | Oct 2010 |         | Limitation on Payments to Influence Certain Federal Transactions (Over $150,000)                                                                         |
| 52.204-4        |         | Aug 2000 |         | Printed or Copied Double-Sided on Recycled Paper (Over $100,000)                                                                                         |
| 52.204-7        |         | Apr 2008 |         | Central Contractor Registration                                                                                                                          |
| 52.204-10       |         | Jul 2010 |         | Reporting Executive Compensation and First-Tier Subcontract Awards ($25,000 or more)                                                                     |
| 52.209-6        |         | Dec 2010 |         | Protecting the Government's Interests When Subcontracting With Contractors Debarred, Suspended, or Proposed for Debarment (Over $30,000)                 |
| 52.215-2        |         | Oct 2010 |         | Audit and Records - Negotiation                                                                                                                          |
| 52.215-8        |         | Oct 1997 |         | Order of Precedence - Uniform Contract Format                                                                                                            |
| 52.215-10       |         | Oct 2010 |         | Price Reduction for Defective Certified Cost or Pricing Data (Over $700,000)                                                                             |
| 52.215-12       |         | Oct 2010 |         | Subcontractor Certified Cost or Pricing Data (Over $700,000)                                                                                             |
| 52.215-14       |         | Oct 2010 |         | Integrity of Unit Prices                                                                                                                                 |
| 52.215-15       |         | Oct 2010 |         | Pension Adjustments and Asset Reversions                                                                                                                 |
| 52.215-18       |         | Jul 2005 |         | Reversion or Adjustment of Plans for Post-Retirement Benefits (PRB) other than Pensions                                                                  |
| 52.215-19       |         | Oct 1997 |         | Notification of Ownership Changes                                                                                                                        |
| 52.215-21       |         | Oct 2010 |         | Requirements for Certified Cost or Pricing Data and Data Other Than Certified Cost or Pricing Data – Modifications                                 |
| 52.216-7        |         | Dec 2002 |         | Allowable Cost and Payment                                                                                                                               |
| 52.216-8        |         | Mar 1997 |         | Fixed Fee                                                                                                                                                |
| 52.219-8        |         | Jan 2011 |         | Utilization of Small Business Concerns (Over $150,000)                                                                                                   |
| 52.219-9        |         | Jan 2011 |         | Small Business Subcontracting Plan (Over $650,000, $1,500,000 for Construction)                                                                          |
| 52.219-16       |         | Jan 1999 |         | Liquidated Damages - Subcontracting Plan                                                                                                                 |
| 52.222-2        |         | Jul 1990 |         | Payment for Overtime Premium (Over $100,000) (Note: The dollar amount in paragraph (a) of this clause is $0 unless otherwise specified in the contract.) |
| 52.222-3        |         | Jun 2003 |         | Convict Labor                                                                                                                                            |
| 52.222-21       |    | Feb 1999 |    | Prohibition of Segregated Facilities                                                                                                                     |

| Contract No. HHSO100201100012C | 23 |
|--------------------------------|----|

----

| 52.222-26 |         | Mar 2007 |         | Equal Opportunity                                                                                                                                                                                                               |
|-----------|--------------|----------|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 52.222-35 |         | Sep 2010 |         | Equal Opportunity for Veterans (Over $100,000)                                                                                                                                                                                  |
| 52.222-36 |         | Oct 2010 |         | Affirmative Action for Workers with Disabilities                                                                                                                                                                                |
| 52.222-37 |         | Sep 2010 |         | Employment Reports Veterans (Over $100,000)                                                                                                                                                                                     |
| 52.222-50 |         | Feb 2009 |         | Combating Trafficking in Persons                                                                                                                                                                                                |
| 52.223-6  |         | May 2001 |         | Drug-Free Workplace                                                                                                                                                                                                             |
| 52.223-14 |         | Aug 2003 |         | Toxic Chemical Release Reporting (Over $100,000)                                                                                                                                                                                |
| 52.225-1  |         | Feb 2009 |         | Buy American Act - Supplies                                                                                                                                                                                                     |
| 52.225-13 |         | Jun 2008 |         | Restrictions on Certain Foreign Purchases                                                                                                                                                                                       |
| 52.227-1  |         | Dec 2007 |         | Authorization and Consent, Alternate I (Apr 1984)                                                                                                                                                                               |
| 52.227-2  |         | Dec 2007 |         | Notice and Assistance Regarding Patent and Copyright Infringement                                                                                                                                                               |
| 52.227-11 |         | Dec 2007 |         | Patent Rights - Ownership by the Contractor (Note: In accordance with FAR 27.303(b)(2), paragraph (e) is modified to include the requirements in FAR 27.303(b)(2)(i) through (iv). The frequency of reporting in (i) is annual. |
| 52.227-14 |         | Dec 2007 |         | Rights in Data - General                                                                                                                                                                                                        |
| 52.232-9  |         | Apr 1984 |         | Limitation on Withholding of Payments                                                                                                                                                                                           |
| 52.232-17 |         | Oct 2010 |         | Interest                                                                                                                                                                                                                        |
| 52.232-20 |         | Apr 1984 |         | Limitation of Cost                                                                                                                                                                                                              |
| 52.232-23 |         | Jan 1986 |         | Assignment of Claims                                                                                                                                                                                                            |
| 52.232-25 |         | Oct 2008 |         | Prompt Payment, Alternate I (Feb 2002)                                                                                                                                                                                          |
| 52.232-33 |         | Oct 2003 |         | Payment by Electronic Funds Transfer—Central Contractor Registration                                                                                                                                                      |
| 52.233-1  |         | Jul 2002 |         | Disputes                                                                                                                                                                                                                        |
| 52.233-3  |         | Aug 1996 |         | Protest After Award, Alternate I (Jun 1985)                                                                                                                                                                                     |
| 52.233-4  |         | Oct 2004 |         | Applicable Law for Breach of Contract Claim                                                                                                                                                                                     |
| 52.242-1  |         | Apr 1984 |         | Notice of Intent to Disallow Costs                                                                                                                                                                                              |
| 52.242-3  |         | May 2001 |         | Penalties for Unallowable Costs (Over $700,000)                                                                                                                                                                                 |
| 52.242-4  |         | Jan 1997 |         | Certification of Final Indirect Costs                                                                                                                                                                                           |
| 52.242-13 |         | Jul 1995 |         | Bankruptcy (Over $150,000)                                                                                                                                                                                                      |
| 52.243-2  |         | Aug 1987 |         | Changes - Cost Reimbursement, Alternate V (Apr 1984)                                                                                                                                                                            |
| 52.244-2  |         | Oct 2010 |         | Subcontracts, Alternate I (June 2007)                                                                                                                                                                                           |
| 52.244-5  |         | Dec 1996 |         | Competition in Subcontracting (Over $150,000)                                                                                                                                                                                   |
| 52.244-6  |         | Dec 2010 |         | Subcontracts for Commercial Items                                                                                                                                                                                               |
| 52.245-1  |         | Aug 2010 |         | Government Property                                                                                                                                                                                                             |
| 52.245-9  |         | Aug 2010 |         | Use and Charges                                                                                                                                                                                                                 |
| 52.246-23 |         | Feb 1997 |         | Limitation of Liability (Over $150,000)                                                                                                                                                                                         |
| 52.249-6  |         | May 2004 |         | Termination (Cost-Reimbursement)                                                                                                                                                                                                |
| 52.249-14 |         | Apr 1984 |         | Excusable Delays                                                                                                                                                                                                                |
| 52.253-1  |    | Jan 1991 |    | Computer Generated Forms                                                                                                                                                                                                        |

| b. | DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CFR CHAPTER 3) CLAUSES: |
|----|----------------------------------------------------------------------------------------------------|

| HHSAR           |         |     |         |                                                  |
|-----------------|--------------|----------|--------------|-------------------------------------------------------|
| CLAUSE NO. |         | DATE     |         | TITLE                                                 |
| 352.202-1       |         | Jan 2006 |         | Definitions - with Alternate paragraph (h) (Jan 2006) |
| 352.203-70      |         | Jan 2006 |         | Anti-Lobbying                                         |
| 352.216-70      |         | Jan 2006 |         | Additional Cost Principles                            |
| 352.227-70      |         | Jan 2006 |         | Publications and Publicity                            |
| 352.228-7       |         | Dec 1991 |         | Insurance - Liability to Third Persons                |
| 352.233-71      |         | Jan 2006 |         | Litigation and Claims                                 |
| 352.242-70      |         | Jan 2006 |         | Key Personnel                                         |
| 352.242-73      |         | Jan 2006 |         | Withholding of Contract Payments                      |
| 352.242-74      |    | Apr 1984 |    | Final Decisions on Audit Findings                     |

| Contract No. HHSO100201100012C | 24 |
|--------------------------------|----|

----

| a. | FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES |
|----|-----------------------------------------------------------------|

|   | (1) | FAR Clause 52.203-13, Contractor Code of Business Ethics and Conduct (April 2010). |
|--------|-----|------------------------------------------------------------------------------------|

|   | (2) | FAR Clause 52.203-14, Display of Hotline Poster(s) (December 2007). |
|--------|-----|---------------------------------------------------------------------|

|   | “.....(3) Any required posters may be obtained as follows: |
|--------|----------------------------------------------------------------------|

| Poster(s)                                  |   | Obtain From"                                             |
|--------------------------------------------|--------|---------------------------------------------------------------|
| HHS Contractor Code of Ethics and Business |   |                                                          |
| Conduct Poster                             |   |  http://oig.hhs.gov/fraud/hotline/OIG_Hotline_Poster.pdf |

|   | (3) | FAR Clause 52.215-17, Waiver of Facilities Capital Cost of Money (October 1997). |
|--------|-----|----------------------------------------------------------------------------------|

|   | (4) | FAR Clause 52.217-9, Option to Extend the Term of the Contract (March 2000). |
|--------|-----|------------------------------------------------------------------------------|

|   | "c) | The total duration of this contract, including the exercise of Option Period One under this clause, shall not exceed 60 months. |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------|

|   | (5) | FAR Clause 52.219-4, Notice of Price Evaluation Preference for HUBZone Small Business Concerns (January 2011). |
|--------|-----|----------------------------------------------------------------------------------------------------------------|

|   | "(c) | Waiver of evaluation preference..... |
|--------|------|--------------------------------------|

|   | (6) | FAR Clause 52.246-8. Inspection of Research and Development–Cost-Reimbursement (May 2001) |
|--------|-----|-------------------------------------------------------------------------------------------------|

| b. | DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CHAPTER 3) CLAUSES: |
|----|------------------------------------------------------------------------------------------------|

|   | (1) | HHSAR Clause 352.201-70, Paperwork Reduction Act (January 2006). |
|--------|-----|------------------------------------------------------------------|

|   | (2) | HHSAR Clause 352.223-70, Safety and Health (January 2006). |
|--------|-----|------------------------------------------------------------|

|   | (3) | HHSAR Clause 352.270-4, Protection of Human Subjects (January 2006). |
|--------|-----|----------------------------------------------------------------------|

|   | (4) | HHSAR Clause 352.270-5, Care of Laboratory Animals (January 2006). |
|--------|-----|--------------------------------------------------------------------|

|   | (5) | HHSAR Clause 352.270-6, Restriction on Use of Human Subjects (January 2006). |
|--------|-----|------------------------------------------------------------------------------|

| Contract No. HHSO100201100012C | 25 |
|--------------------------------|----|

----

| Contract No. HHSO100201100012C | 26 |
|--------------------------------|----|

----

| Contract No. HHSO100201100012C | 27 |
|--------------------------------|----|

----

| Attachment No. |   | Title                                                                                                     |   |                                                |
|----------------|--------|-----------------------------------------------------------------------------------------------------------|--------|-----------------------------------------------------|
|           |   |                                                                                                      |   |                                                |
| Attachment 1:  |   | Invoice/Financing Request Instructions for  – Cost-Reimbursement Type Contracts (4 pages) |   | See Attachment Section at the end of this contract. |
|           |   |                                                                                                      |   |                                                |
| Attachment 2:  |   | Financial Report of Individual Project/Contract and Instructions (4 pages)                                |   | Provided as a separate document.                    |
|           |   |                                                                                                      |   |                                                |
| Attachment 3:  |   | Report of Government Owned Contractor Held Property (1 page)                                              |   | Provided as a separate document.                    |
|           |   |                                                                                                      |   |                                                |
| Attachment 4:  |   | Contractor Defined Milestones (February 4, 2011, 5 pages)                                                 |   | Provided as a separate document.                    |

| Contract No. HHSO100201100012C | 28 |
|--------------------------------|----|

----